Stephens Inc. AR lessened its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 2.0% during the first quarter, Holdings Channel reports. The institutional investor owned 7,445 shares of the medical research company’s stock after selling 155 shares during the period. Stephens Inc. AR’s holdings in Edwards Lifesciences were worth $1,424,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in the business. Gofen & Glossberg LLC IL lifted its holdings in Edwards Lifesciences by 21.1% in the fourth quarter. Gofen & Glossberg LLC IL now owns 2,429 shares of the medical research company’s stock worth $372,000 after acquiring an additional 424 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in Edwards Lifesciences by 276.3% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,505 shares of the medical research company’s stock worth $230,000 after acquiring an additional 1,105 shares during the last quarter. Quadrant Capital Group LLC lifted its holdings in Edwards Lifesciences by 10.7% in the fourth quarter. Quadrant Capital Group LLC now owns 1,257 shares of the medical research company’s stock worth $182,000 after acquiring an additional 121 shares during the last quarter. Peregrine Capital Management LLC lifted its holdings in Edwards Lifesciences by 2.6% in the fourth quarter. Peregrine Capital Management LLC now owns 103,618 shares of the medical research company’s stock worth $15,871,000 after acquiring an additional 2,580 shares during the last quarter. Finally, Capital Investment Advisors LLC bought a new position in Edwards Lifesciences in the fourth quarter worth about $259,000. Hedge funds and other institutional investors own 84.43% of the company’s stock.
Shares of NYSE:EW opened at $173.12 on Friday. Edwards Lifesciences Corp has a 12 month low of $134.38 and a 12 month high of $197.86. The company has a market cap of $36.93 billion, a P/E ratio of 36.83, a PEG ratio of 2.27 and a beta of 0.85. The company has a current ratio of 3.66, a quick ratio of 2.69 and a debt-to-equity ratio of 0.17.
A number of equities analysts have issued reports on EW shares. Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a report on Monday, February 4th. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 target price on shares of Edwards Lifesciences in a report on Sunday, February 3rd. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $180.00 to $190.00 in a report on Friday, January 18th. Canaccord Genuity reaffirmed a “buy” rating and set a $215.00 price target (up previously from $190.00) on shares of Edwards Lifesciences in a report on Monday, March 18th. Finally, Jefferies Financial Group lifted their price target on Edwards Lifesciences from $195.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $187.00.
In related news, VP Catherine M. Szyman sold 1,474 shares of the business’s stock in a transaction that occurred on Thursday, February 21st. The stock was sold at an average price of $176.34, for a total transaction of $259,925.16. Following the sale, the vice president now owns 15,905 shares of the company’s stock, valued at $2,804,687.70. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 32,800 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $167.89, for a total value of $5,506,792.00. Following the sale, the chief executive officer now directly owns 67,126 shares in the company, valued at approximately $11,269,784.14. The disclosure for this sale can be found here. In the last three months, insiders have sold 153,780 shares of company stock worth $27,129,483. 1.63% of the stock is owned by corporate insiders.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Read More: FAANG Stocks
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.